| Ytd | -19.35% | |
| 1y | 145.85% |
| Open | 11.49 | Prev Close | 11.45 | Low | 10.54 | High | 11.55 | Mkt Cap | 401.72M |
| Vol | 738.21K | Avg Vol | 827.35K | EPS | -2.38 | P/E | -4.48 | Forward P/E | -12.08 |
| Beta | 0.93 | Short Ratio | 4.63 | Inst. Own | 85.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 19.70 | 200-d Avg | 16.70 | 1yr Est | 49.50 |
BIOA News
BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensu
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst cons
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measur
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the pri
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concer
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio
US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report)'s stock price rose 5.5% on Friday. The stock trad
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral do
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Con
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "th
Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes.
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology s
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascu
BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, a
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among or
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical da
BioAge Labs (NASDAQ: BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 i
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor
BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 d
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the s
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in part
BioAge Labs is rated Buy, leveraging strong early data for BGE-102, a novel oral NLRP3 inhibitor tar
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear
